PULS changes its name to AQILION AB

Today the company Partners för Utvecklingsinvesteringar inom Life Science, P.U.L.S. AB is changing its name to AQILION AB. The name change marks a new phase in the development of the company, with a new strategy and identity. The decision…

Glactone Pharma: STAT3 interacts with the androgen receptor and is a drug target in enzalutamide resistant prostate cancer

In collaboration with researchers at Vancouver Prostate Centre in Canada, Glactone Pharma has discovered a novel way of enhancing the effects of current prostate cancer treatments. The research, published in the scientific journal Scientific…

Glactone Pharma: STAT3 interagerar med androgenreceptorn och är en läkemedelsmåltavla i enzalutamide-resistent prostatacancer

I samarbete med forskare vid Vancouver Prostate Centre i Kanada har Glactone Pharma upptäckt ett nytt sätt att förstärka effekter av existerande prostatacancerbehandlingar. Forskningen, som publicerats i den vetenskapliga tidskriften Scientific…

Oncorena raises SEK 14.5 million to prepare for clinical study in advanced kidney cancer

Oncorena Holding AB today announces that the company through a share issue has raised capital to build its organization and resources in preparation for clinical development with a patient study of a new treatment modality for advanced kidney…